{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-169612","form_type":"8-K","ticker":"VERA","cik":"0001831828","company_name":"Vera Therapeutics, Inc.","filed_at":"2023-06-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.984064+00:00","generated_at":"2026-06-13T21:43:14.650085+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Vera's atacicept shows 43% placebo-adjusted proteinuria reduction at week 36 in Phase 2b IgAN trial","bullets":["Atacicept 150 mg achieved 43% placebo-adjusted UPCR reduction (PP, p=0.003) and 35% (ITT, p=0.012).","Patients on atacicept had stable eGFR vs. placebo decline; delta 11% (p=0.038), 5.8 mL/min/1.73 m² difference.","Gd-IgA1 reduced 64% from baseline (p<0.0001); safety consistent with prior studies, low SAE rate (3% vs 9% placebo).","Phase 3 ORIGIN 3 trial initiated June 2023; topline results expected H1 2025, BLA submission H2 2025.","Company targets commercial launch in 2026 if atacicept receives FDA approval for IgAN."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-169612","json":"https://secwatch.observer/filing/0001193125-23-169612.json","markdown":"https://secwatch.observer/filing/0001193125-23-169612.md","text":"https://secwatch.observer/filing/0001193125-23-169612.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1831828/000119312523169612/0001193125-23-169612-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1831828/000119312523169612/d522707d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T21:43:14.650085+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}